Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elham Ahmadi

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
International Journal of Molecular Sciences|November 25, 2023
Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active SurveillanceElham Ahmadi, Simon Wang, Mohammad Gouran-Savadkoohi, et al.
Cancer Research|May 17, 2023
The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in CancerSahar Mafi, Elham Ahmadi, Eileen Meehan, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Computation-aided Design of Rod-Shaped Janus Base Nanopieces for Improved Tissue Penetration and Therapeutics DeliveryJinhyung Lee, Wuxia Zhang, Danh Nguyen, et al.
Translational Oncology|September 3, 2021
Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant dosesEvangelia E Tsakiridis, Lindsay Broadfield, Katarina Marcinko, et al.
Communications Biology|September 8, 2023
The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapyAmr Ali, Bassem Mekhaeil, Olga-Demetra Biziotis, et al.
JHEP Reports : Innovation in Hepatology|April 25, 2025
Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinomaEvangelia E Tsakiridis, Elham Ahmadi, Jaya Gautam, et al.
Molecular Oncology|August 16, 2023
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1αOlga-Demetra Biziotis, Evangelia Evelyn Tsakiridis, Amr Ali, et al.
Journal of Leukocyte Biology|March 4, 2026
HER2-Specific Synthetic Antigen Receptor (SAR) T Cell Therapy Synergizes with Radiotherapy to Provide Improved Anti-Tumor Efficacy in Non-Small Cell Lung Cancer (NSCLC)Olga-Demetra Biziotis, Christopher M Silvestri, Allyson E Moore, et al.
Cell Reports. Medicine|September 20, 2023
Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in miceEric M Desjardins, Jianhan Wu, Declan C T Lavoie, et al.
Radiation Oncology (London, England)|November 8, 2024
Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapyFiorella Di Pastena, Gregory Pond, Evangelia E Tsakiridis, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
International Journal of Molecular Sciences|November 25, 2023
Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active SurveillanceElham Ahmadi, Simon Wang, Mohammad Gouran-Savadkoohi, et al.
Cancer Research|May 17, 2023
The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in CancerSahar Mafi, Elham Ahmadi, Eileen Meehan, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Computation-aided Design of Rod-Shaped Janus Base Nanopieces for Improved Tissue Penetration and Therapeutics DeliveryJinhyung Lee, Wuxia Zhang, Danh Nguyen, et al.
Translational Oncology|September 3, 2021
Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant dosesEvangelia E Tsakiridis, Lindsay Broadfield, Katarina Marcinko, et al.
Communications Biology|September 8, 2023
The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapyAmr Ali, Bassem Mekhaeil, Olga-Demetra Biziotis, et al.
JHEP Reports : Innovation in Hepatology|April 25, 2025
Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinomaEvangelia E Tsakiridis, Elham Ahmadi, Jaya Gautam, et al.
Molecular Oncology|August 16, 2023
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1αOlga-Demetra Biziotis, Evangelia Evelyn Tsakiridis, Amr Ali, et al.
Journal of Leukocyte Biology|March 4, 2026
HER2-Specific Synthetic Antigen Receptor (SAR) T Cell Therapy Synergizes with Radiotherapy to Provide Improved Anti-Tumor Efficacy in Non-Small Cell Lung Cancer (NSCLC)Olga-Demetra Biziotis, Christopher M Silvestri, Allyson E Moore, et al.
Cell Reports. Medicine|September 20, 2023
Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in miceEric M Desjardins, Jianhan Wu, Declan C T Lavoie, et al.
Radiation Oncology (London, England)|November 8, 2024
Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapyFiorella Di Pastena, Gregory Pond, Evangelia E Tsakiridis, et al.
Pageof 11